Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genomma Lab InternacionalB de CV's operating cash flow per share for the
three
months ended in Jun. 2026 was MXN0.39.
Genomma Lab InternacionalB de CV's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was MXN1.89.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Genomma Lab InternacionalB de CV was -41.40% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 0.50% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 10.40% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 7.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's Operating Cash Flow per Share or its related term are showing as below:
MEX:LABB'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -31 Med: 10.65 Max: 140.8
Current: 0.5
During the past 13 years, Genomma Lab InternacionalB de CV's highest 3-Year average Operating Cash Flow per Share Growth Rate was 140.80% per year. The lowest was -31.00% per year. And the median was 10.65% per year.
MEX:LABB's 3-Year OCF Growth Rate is ranked worse than 61.34% of 763
companies
in the Drug Manufacturers industry
Industry Median: 7.2
vs MEX:LABB: 0.50
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV Operating Cash Flow per Share Chart
MEX:LABB vs ZTS, UTHR, VTRS: Operating Cash Flow per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Price-to-Operating-Cash-Flow vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1.89
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of MXN1.89 mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a Operating Cash Flow per Share of MXN1.89 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Genomma Lab InternacionalB de CV and its competitors. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #468 out of 763 companies in the Drug Manufacturers industry, placing it in the top 61.3%.
Is Genomma Lab InternacionalB de CV's Operating Cash Flow per Share too high?
Genomma Lab InternacionalB de CV's current Operating Cash Flow per Share is MXN1.89. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #468 out of 763 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Operating Cash Flow per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #468 out of 763 companies for Operating Cash Flow per Share. This places Genomma Lab InternacionalB de CV in the lower half of its industry. The industry median Operating Cash Flow per Share is 7.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Drug Manufacturers company?
The median Operating Cash Flow per Share among Drug Manufacturers companies is 7.20, based on 763 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median Operating Cash Flow per Share is 7.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Operating Cash Flow per Share is MXN1.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.26, compared to a current price of MXN14.61 — trading 15.4% below its estimated fair value. The current Operating Cash Flow per Share is MXN1.89. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Operating Cash Flow per Share is MXN1.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN14.61 is trading 15.4% below its estimated GF Value™ of MXN17.26.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Operating Cash Flow per Share: MXN1.89
GF Value™: MXN17.26 vs. price of MXN14.61 (15.4% below fair value)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
